Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.550
-0.020 (-0.44%)
At close: May 29, 2026, 4:00 PM EDT
4.555
+0.005 (0.11%)
After-hours: May 29, 2026, 5:40 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Aclaris Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $9.67. The average 1-year stock price forecast is 112.53% higher than the current stock price, while the lowest is $4.00 (-12.09%) and the highest is $16 (+251.65%).
Price Target: $9.67 (+112.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 7 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 9 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $11 | Buy | Maintains | $11 | +141.76% | May 11, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $12 | Buy | Reiterates | $12 | +163.74% | May 11, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $16 | Buy | Reiterates | $16 | +251.65% | May 11, 2026 |
| Wedbush | Wedbush | Buy Maintains $10 | Buy | Maintains | $10 | +119.78% | May 8, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $10 | Buy | Reiterates | $10 | +119.78% | May 8, 2026 |
Financial Forecast
Revenue This Year
6.43M
from 7.83M
Decreased by -17.84%
Revenue Next Year
6.05M
from 6.43M
Decreased by -5.91%
EPS This Year
-0.64
from -0.53
EPS Next Year
-0.68
from -0.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 9.5M | 12.6M | ||||||
| Avg | 6.4M | 6.1M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 21.4% | 96.0% | ||||||
| Avg | -17.8% | -5.9% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.50 | -0.47 | |||
| Avg | -0.64 | -0.68 | |||
| Low | -0.69 | -0.83 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.